Horizon Therapeutics
09.09.19
FDA Grants Priority Review of Horizon Therapeutics’ Teprotumumab BLA for the Treatment of Active Thyroid Eye Disease (TED)Source: Horizon Therapeutics
08.19.19
American Journal of Ophthalmology Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)Source: Horizon Therapeutics
08.02.19
Horizon Therapeutics’ Teprotumumab Expanded for Use in Active Thyroid Eye Disease (TED)Source: Horizon Therapeutics
07.10.19
Horizon Therapeutics Submits Biologics License Application for the Treatment of Active Thyroid Eye DiseaseSource: Horizon Therapeutics